Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Hiring of New Pharmacists Sluggish Due to Decreasing Numbers of Applicants, Tough Competition: Major Dispensing Pharmacies
April 18, 2012
- Eisai Launches Insomnia Treatment Lunesta
April 18, 2012
- Daiichi Sankyo Launches Ranmark for Treatment of Bone Lesions Associated with Cancer; AZ to Copromote Product
April 18, 2012
- Eli Lilly Japan Pinning New Hopes on Solanezumab; Will the Introduction of Medicoeconomic Assessments Help?
April 18, 2012
- MediBIC and Kobe University Hospital to Jointly Form Conference on Pharmacogenomics
April 17, 2012
- JCSOA to Draw Up Guideline for Coping with Business Conflicts this Year
April 17, 2012
- Actelion Receives Approval for NPC Treatment
April 17, 2012
- Ajinomoto Pharmaceuticals to Distribute Lentinan from July: Ajinomoto, Taiho
April 17, 2012
- Generic Names Used in 25% of Prescriptions Issued by GPs: Nihon Chouzai
April 17, 2012
- National, Rosai Hospitals to Buy 9,000 Products in First Joint Purchasing, HQ to Buy Generics by Bulk
April 16, 2012
- Elmed Eisai Found to Make Good Impression on Pharmacists: Survey
April 16, 2012
- Over 60% of Drug Makers Increased Hiring of New Graduates in 2012: Jiho Survey
April 16, 2012
- Ain Pharmaciez to Introduce Electronic Drug Notebooks at All Its Group Stores in July
April 16, 2012
- Takeda to Acquire URL Pharma, Boost US Business Base Through Field of Gout
April 13, 2012
- ECI to Initiate Clinical Research for Cancer Therapy ECI301
April 13, 2012
- AnGes MG to Codevelop High Blood Pressure Treatment Oral Vaccine with Korean Company
April 13, 2012
- US Subsidiary’s CEO Resigns: DSP
April 13, 2012
- AnGes MG Obtains Pharmaceutical Use Patent in Japan for NF-κB Decoy Oligo
April 13, 2012
- Pfizer Focuses on Personalized Medicine for Oncology Area with Xalkori
April 12, 2012
- Teijin Pharma to Expand Overseas Marketing of Febuxostat in 117 Countries
April 12, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…